{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-045577","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2024-04-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.615740+00:00","generated_at":"2026-06-04T00:20:47.362720+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Carisma reports preliminary Phase 1 data for CT-0508; 40.7% target lesion reduction in monotherapy","bullets":["In 14 monotherapy patients, 40.7% of target lesions reduced in size on ≥1 scan across all anatomic sites.","Combination sub-study of CT-0508 with pembrolizumab enrolled 6 patients; data from first 3 shown.","First two combination patients received corticosteroids prior to pembro; both had progressive disease as best response.","Third combination patient achieved stable disease with 46% reduction in one target lesion; PD due to new brain met.","Company notes corticosteroids may reverse CT-0508 activity based on in vitro cell death data."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-045577","json":"https://secwatch.observer/filing/0001104659-24-045577.json","markdown":"https://secwatch.observer/filing/0001104659-24-045577.md","text":"https://secwatch.observer/filing/0001104659-24-045577.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924045577/0001104659-24-045577-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924045577/tm2411506d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:20:47.362720+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}